Backed by MPM Capital and Sofinnova, immuno-oncology specialist iOmx Therapeutics has raised €40m in its first round of financing. The German company had just been founded in spring.
German immuno-oncology play BioNTech has entered into a collaboration with Roche’s Genentech to develop novel mRNA-based, individualised cancer vaccines. The deal will net BioNTech €278m.
Prexton Therapeutics is taking aim at Phase II: The Swiss company happily presented results for its Phase I trial of its mGluR4 positive allosteric modulator in Parkinson’s Disease, saying the first-in-class compound proved to be safe and well tolerated.
Denmark’s Novozymes has acquired microbial research company Organobalance GmbH. The German company owns a large collection of microbial strains, some of which date back to the 1920s, and has strong capabilities in microbial screening and assay technology.
14.09.2016 – The summer slump on the stock markets is over: AC Immune has confidently priced its long-awaited Nasdaq IPO. The Swiss Alzheimer’s specialist is expecting to raise up to US$68m (€60.5m) overseas.
13.09.2016 – Diabetes major Sanofi is joining forces with Verily – formerly Google Life Sciences – to launch Onduo. The joint venture will develop a comprehensive diabetes management platform.
09.09.2016 – iBionext’s healthcare VC fund iBionext Growth has announced a first closing of €46m. All in all, iBionext aims to take in around €100m to reinvest in biotech and medtech companies.
07.09.2016 – Furniture giant Ikea and renewables expert Neste have joined forces to deliver bio-based plastics based on Neste’s bio-based polymer. The partners urge other companies to join the initiative.
06.09.2016 – DBV’s needle-free patch technology is being put to the test in a a proof of concept trial for a pertussis vaccine developed by BioNet-Asia. Researchers from the Geneva University Hospital are supervising the study.
05.09.2016 – Why do people grow old? Italian researchers took a close look at centenarians and found that low levels of the peptide hormone Adrenomedullin may significantly contribute towards good microcirculation and thus longevity.